Details for Patent: 8,377,952

Title:	Solid pharmaceutical dosage formulation
Abstract:	The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
Inventor(s):	Rosenberg; Joerg (Ellerstadt, DE), Reinhold; Ulrich (Aachen, DE), Liepold; Bernd (Heidelberg, DE), Berndl; Gunther (Herxheim, DE), Breitenbach; Jorg (Mannheim, DE), Alani; Laman L. (Lansdale, PA), Ghosh; Soumojeet (Lansdale, PA)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Filing Date:	Feb 23, 2005
Application Number:	11/064,467
Claims:	1. A method of treating HIV, comprising administering, to a patient in need thereof a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food or under a fasting condition, and wherein said dosage form comprises a solid solution or solid dispersion of lopinavir and ritonavir in a matrix, said matrix comprising at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, wherein said surfactant is sorbitan monolaurate, and said water-soluble polymer has a Tg of at least 50.degree. C. 2. The method of claim 1, wherein each of said at least one pharmaceutically acceptable water-soluble polymer has a Tg of at least 50.degree. C. 3. The method of claim 2, wherein said at least one pharmaceutically acceptable water-soluble polymer comprises a copolymer of N-vinyl pyrrolidone and vinyl acetate. 4. The method of claim 2, wherein said at least one pharmaceutically acceptable water-soluble polymer comprises copovidone. 5. The method of claim 1, wherein said dosage form comprises a solid solution of lopinavir and ritonavir in said matrix. 6. The method of claim 5, wherein each of said at least one pharmaceutically acceptable water-soluble polymer has a Tg of at least 50.degree. C. and each of said at least one pharmaceutically acceptable surfactant has an HLB value of from 4 to 10. 7. The method of claim 6, wherein said at least one pharmaceutically acceptable surfactant accounts for at least 50% by weight of the total amount of surfactants comprised in said dosage form. 8. The method of claim 6, wherein said dosage form comprises from 50 to 85% by weight of the dosage form of said at least one pharmaceutically acceptable water-soluble polymer, and from 2 to 20% by weight of the dosage form of said at least one pharmaceutically acceptable surfactant. 9. The method of claim 8, wherein said at least one pharmaceutically acceptable water-soluble polymer comprises a copolymer of N-vinyl pyrrolidone and vinyl acetate. 10. The method of claim 8, wherein said at least one pharmaceutically acceptable water-soluble polymer is copovidone. 11. A method of treating HIV, comprising administering to a patient in need thereof a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food or under a fasting condition, and said dosage form comprises a solid solution or solid dispersion of lopinavir and ritonavir in a matrix, said matrix comprising sorbitan monolaurate and a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., and wherein when said dosage form is dissolved in vitro using a USP apparatus 2 (paddle) at 75 rpm with a 0.06M POEIOLE (Polyoxyethylene 10 Lauryl Ether) medium at 37.degree. C., 20% to 30% of lopinavir in said dosage form is released from 0 to 15 minutes, or 43% to 63 % of lopinavir in said dosage form is released from 15 to 30 minutes, or 61.3% to 81.7% of lopinavir in said dosage form is released from 30 to 45 minutes, or 75.4% to 93.2% of lopinavir in said dosage form is released from 45 to 60 minutes, and wherein when said dosage form is dissolved in vitro using a USP apparatus 2 (paddle) at 75 rpm with a 0.06M POE10LE (Polyoxyethylene 10 Lauryl Ether) medium at 37.degree. C., from 19.8% to 34.4% of ritonavir in said dosage form is released from 0 to 15 minutes, or from 41.6% to 76.5% of ritonavir in said dosage form is released from 15 to 30 minutes, or from 59.4% to 91.1% of ritonavir in said dosage form is released from 30 to 45 minutes, or from 73.4% to 95% of ritonavir in said dosage form is released from 45 to 60 minutes. 12. A method of treating HIV, comprising administering to a patient in need thereof a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food or under a fasting condition, and said dosage form comprises a solid solution or solid dispersion of lopinavir and ritonavir in a matrix, said matrix comprising sorbitan monolaurate and a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., and wherein upon administration of said dosage form to each member of a study population, the mean of lopinavir AUC.infin. (fed) over lopinavir AUC.infin. (fasted) ratios for all members of the study population is from 0.7 to 1.43. 13. A method of treating HIV, comprising administering to a patient in need thereof a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food or under a fasting condition, and said dosage form comprises a solid solution or solid dispersion of lopinavir and ritonavir in a matrix, said matrix comprising sorbitan monolaurate and a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., and wherein upon administration of said dosage form to each member of a study population, the mean of lopinavir Cmax (fed) over lopinavir Cmax (fasted) ratios for all members of the study population is from 0.7 to 1.43. 14. A method of treating an HIV patient, comprising administering to said patient a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food, wherein said dosage form comprises at least one HIV protease inhibitor formulated in solid solution, said solid solution comprising at least one pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C. and sorbitan monolaurate, and wherein said at least one HIV protease inhibitor comprises lopinavir and ritonavir. 15. The method of claim 14, wherein each of said at least one pharmaceutically acceptable water-soluble polymer has a Tg of at least 50.degree. C.. 16. The method of claim 15, wherein said at least one pharmaceutically acceptable water-soluble polymer comprises a copolymer of N-vinyl pyrrolidone and vinyl acetate. 17. The method of claim 15, wherein said dosage form comprises from 50 to 85% by weight of the dosage form of said at least one pharmaceutically acceptable water-soluble polymer, and from 2 to 20% by weight of the dosage form of said sorbitan monolaurate. 18. The method of claim 17, wherein said at least one pharmaceutically acceptable water-soluble polymer is copovidone. 19. A method of treating an HIV patient, comprising administering to said patient a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food, wherein said dosage form comprises ritonavir and lopinavir formulated in solid solution or solid dispersion, said solid solution or solid dispersion comprising a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C. and sorbitan monolaurate. 20. The method of claim 19, wherein said water-soluble polymer is copolymer of N-vinyl pyrrolidone and vinyl acetate. 21. A method of claim 20, wherein said ritonavir and lopinavir are present in an amount from 5% to 30% by weight of the dosage form, said copolymer of N-vinyl pyrrolidone and vinyl acetate is present from 50% to 85% by weight of the dosage form, and said sorbitan monolaurate is present from 2% to 20% by weight of the dosage form. 22. The method of claim 19, wherein said water-soluble polymer is copovidone. 23. The method of claim 22, wherein said solid solution or solid dispersion comprises 4.17 weight % ritonavir, 16.67 weight % lopinavir, 71.16 weight % copovidone, and 7.0 weight % sorbitan monolaurate. 24. The method of claim 22, wherein said solid solution or solid dispersion is a solid solution. 25. The method of claim 19, wherein said solution or solid dispersion is solid solution. 26. The method of claim 21, wherein said solution or solid dispersion is solid solution. 27. The method of claim 26, wherein said water soluble polymer is copovidone. 28. The method of claim 23, wherein said solution or solid dispersion is solid solution. 29. A method of treating an HIV patient, comprising administering to said patient a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food, wherein said dosage form comprises ritonavir and lopinavir formulated in solid solution or solid dispersion, said solid solution or solid dispersion comprising a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C. and sorbitan monopalmitate. 30. The method of claim 29, wherein said water-soluble polymer is copolymer of N-vinyl pyrrolidone and vinyl acetate. 31. A method of claim 30, wherein said ritonavir and lopinavir are present in an amount from 5% to 30% by weight of the dosage form, said copolymer of N-vinyl pyrrolidone and vinyl acetate is present from 50% to 85% by weight of the dosage form, and said sorbitan monopalmitate is present from 2% to 20% by weight of the dosage form. 32. The method of claim 31, wherein said water-soluble polymer is copovidone. 33. The method of claim 29, wherein said solid solution or solid dispersion is solid solution. 34. The method of claim 31, wherein said solid solution or solid dispersion is solid solution. 35. The method of claim 32, wherein said solution or solid dispersion is solid solution.